Quantity of suitable sufferers: CDEC reviewed the uncertainty in the amount of people with reasonably intense to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some patients who will be categorized as getting mild or average sickness could possibly have a critical… Read More